

HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi)

General Information

Synonyms:	CTAG1;CT6.1;CTAG1B;LAGE2A;MY-ESO-1;LAGE-2;MHC;NY-ESO-1;ESO1CTAG
Protein Construction:	Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and SLLMWITQV peptide
Species:	Human
Expression Host:	HEK293 Cells
Accession:	A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQV
Molecular Weight:	The protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer, His Tag at 5 μ g/ml (100 μ l/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Antibody, hFc Tag with the EC50 of 6.0ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1 EU/ μ g by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μ m filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μ g/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Shipping:

In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.

Protein Background

NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.

Reference

Thomas R, et al. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. *Front Immunol.* 2018 May 1;9: 947. doi: 10.3389/fimmu.2018.00947. PMID: 29770138; PMCID: PMC5941317.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_email:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481